Evidence map›Paper›PMID 36864688›Full record

ArticleBrain : a journal of neurology2023

The radiologically isolated syndrome: revised diagnostic criteria.

Christine Lebrun-Frénay, Darin T Okuda, Aksel Siva, Cassandre Landes-Chateau, Christina J Azevedo, Lydiane Mondot, Clarisse Carra-Dallière, Helene Zephir, Celine Louapre, Françoise Durand-Dubief and 16 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Christine Lebrun-FrénayNeurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.ORCID 0000-0002-3713-2416
Darin T OkudaNeuroinnovation Program, Multiple Sclerosis, and Neuroimmunology Imaging Program, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-6499-1523
Aksel SivaDepartment of Neurology, Istanbul University Cerrahpasa School of Medicine, 34098 Istanbul, Turkey.
Cassandre Landes-ChateauNeurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
Christina J AzevedoKeck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Lydiane MondotNeurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
Clarisse Carra-DallièreNeurology MS Clinic, Montpellier University Hospital, 34295 Montpellier, France.
Helene ZephirInserm UMR-S 1172 LilNcog, Lille University, Lille University Hospital Precise, 59000 Lille, France.
Celine LouapreDepartment of Neurology, Sorbonne University, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Françoise Durand-DubiefNeurology MS Clinic, Neurological Hospital Pierre Wertheimer, Lyon University Hospital, 69500 Lyon/Bron, France.
Emmanuelle Le PageNeurology MS Clinic Rennes, Clinical Investigation Centre CIC-P 1414, Rennes University Hospital, 35000 Rennes, France.
Caroline BensaNeurology, Rothschild Foundation, 75019 Paris, France.
Aurélie RuetNeurology MS Clinic Bordeaux, University Hospital, 33000 Bordeaux, France.
Jonathan CironNeurology MS Clinic, Toulouse University Hospital, 31300 Toulouse, France.
David A LaplaudNeurology, Nantes University Hospital, CIC1314 INSERM, 44000 Nantes, France.
Olivier CasezNeurology MS Clinic Grenoble, Grenoble Alpes University Hospital, 38700 Grenoble, France.
Guillaume MatheyNeurology, Nancy University Hospital, 54000 Nancy, France.
Jerome de SezeClinical Investigation Center, Neurology, Strasbourg University Hospital, INSERM 1434, 67200 Strasbourg, France.
Burcu ZeydanNeurology and Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-2270-9868
Naila MakhaniPediatrics and Neurology, Yale School of Medicine, New Haven, CT 06510, USA.
Melih TutuncuDepartment of Neurology, Istanbul University Cerrahpasa School of Medicine, 34098 Istanbul, Turkey.
Michael LevrautNeurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
Mikael CohenNeurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.
Eric ThouvenotNeurology, Nîmes University Hospital, 30900 Nîmes, France.
Daniel PelletierKeck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Orhun H KantarciNeurology, Mayo Clinic, Rochester, MN 55905, USA.

Funding

The Radiologically Isolated Syndrome in ChildrenK23NS101099 · NINDS · YALE UNIVERSITY · PI MAKHANI, NAILA · 2017 to 2022
$792k
NINDS NIH HHS K23 NS101099
6 · The paper itself

Abstract

The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1-2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.

Indexed as

Demyelinating DiseasesMultiple SclerosisAdultDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedRisk Factorsdiagnostic criteriaMRImultiple sclerosisprognosisradiologically isolated syndrome

Identifiers

PMID36864688
PMCPMC11004931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.